Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SMMT Summit Therapeutics PLC

盘前交易 12-05 04:56:03 EST

18.81

+0.44

+2.40%

最高18.99	最低18.19	成交量278.24万
今开18.29	昨收18.37	日振幅4.35%
总市值145.03亿	流通市值24.26亿	总股本7.71亿
成交额5,203万	换手率2.16%	流通股本1.29亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SMMT","market":"US","secType":"STK","nameCN":"Summit Therapeutics PLC","latestPrice":18.81,"timestamp":1764882000000,"preClose":18.37,"halted":0,"volume":2782408,"delay":0,"floatShares":129000000,"shares":771000000,"eps":-1.250689,"marketStatus":"盘前交易","change":0.44,"latestTime":"12-05 04:56:03 EST","open":18.29,"high":18.99,"low":18.19,"amount":52027996.77528,"amplitude":0.043549,"askPrice":19.45,"askSize":100,"bidPrice":18.81,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.250689,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1764945000000},"marketStatusCode":1,"adr":1,"adrRate":5,"listingDate":1425531600000,"exchange":"NASDAQ","adjPreClose":18.81,"postHourTrading":{"tag":"盘后","latestPrice":18.9,"preClose":18.81,"latestTime":"19:59 EST","volume":51737,"amount":973236.359,"timestamp":1764896359133},"volumeRatio":1.1896894109441816,"impliedVol":1.1319,"impliedVolPercentile":0.8916},"requestUrl":"/m/hq/s/SMMT","defaultTab":"news","newsList":[{"id":"1158928922","title":"Summit Therapeutics申请最多2670万股普通股的配售 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1158928922","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158928922?lang=zh_cn&edition=full","pubTime":"2025-10-30 05:14","pubTimestamp":1761772463,"startTime":"0","endTime":"0","summary":"Summit Therapeutics申请最多2670万股普通股的配售，售出股东将在SEC备案中进行披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","SMMT","BK4139"],"gpt_icon":0},{"id":"2578752044","title":"中外制药获得部分IgA肾病药物权利，峰会治疗公司筹集5亿美元Chugai Pharmaceutical Gains Partial Rights to IgA Nephropathy Drug as Summit Therapeutics Raises $500 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2578752044","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578752044?lang=zh_cn&edition=full","pubTime":"2025-10-24 23:08","pubTimestamp":1761318480,"startTime":"0","endTime":"0","summary":"by Mark Chiang马克·蒋Share To分享到Chugai Pharmaceutical has secured partial rights to a drug used in the treatment of IgA nephropathy, a chronic kidney disease. The acquisition involves a marketed therapy aimed at addressing this condition. Meanwhile, the Institute for Clinical and Economic Review  released findings suggesting that Americans are frequently paying higher-than-necessary prices for medications.中外制药获得了用于治疗IgA肾病的药物的部分权利。Additionally, Summit Therapeutics announced it has raised $500 million in funding..此外，Summit Therapeutics宣布已筹集5亿美元资金。The developments highlight ongoing activity within the pharmaceutical sector. Chugai’s move reflects continued interest in therapies targeting renal diseases, while ICER’s report underscores concerns about drug pricing trends in the U.S. Summit’s funding round marks a significant financial milestone for the company as it seeks to advance its pipeline of treatments.这些进展突显了制药行业内的持续活跃。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102423101194dbd593&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102423101194dbd593&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SMMT","BK4139","BK4539","LU2488822045.USD","BK4007"],"gpt_icon":0},{"id":"2576865028","title":"Summit Thera三季度每股亏损0.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576865028","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576865028?lang=zh_cn&edition=full","pubTime":"2025-10-20 23:29","pubTimestamp":1760974140,"startTime":"0","endTime":"0","summary":"美股周一早盘，生物制药企业Summit Therapeutics（SMMT）股价下跌4.9%，此前该公司报告第三季度每股亏损0.13美元，未达预期。尽管盈利不及预期，公司现金储备依然雄厚，支持其持续的战略计划。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-10-20/doc-infuqfta5063279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2488822045.USD","SMMT","SINA","BK4139"],"gpt_icon":0},{"id":"1182230580","title":"Summit Therapeutics股票因未披露肺癌试验整体生存数据和第三季度业绩下跌7.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182230580","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182230580?lang=zh_cn&edition=full","pubTime":"2025-10-20 21:34","pubTimestamp":1760967262,"startTime":"0","endTime":"0","summary":"Summit Therapeutics股票因未披露肺癌试验整体生存数据和第三季度业绩下跌7.7%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","BK4139","LU2488822045.USD"],"gpt_icon":0},{"id":"1136397665","title":"异动解读 | Summit Therapeutics盘前大跌5.67%，新临床试验计划和财报引发投资者担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1136397665","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136397665?lang=zh_cn&edition=full","pubTime":"2025-10-20 19:10","pubTimestamp":1760958633,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC今日盘前大跌5.67%，引发市场关注。该公司今日早间发布了两则重要公告，可能是导致股价下跌的原因。首先，Summit Therapeutics宣布将启动一系列新的III期Harmoni-Gi3临床试验，但详细信息要到2026年第一季度才会公布。这一消息可能引发了投资者对公司研发进展的担忧。其次，公司同时发布了2025年第三季度及截至9月30日的九个月财务结果和运营进展报告。市场似乎对Summit Therapeutics的短期前景持谨慎态度，这反映在盘前的显著跌幅上。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SMMT"],"gpt_icon":0},{"id":"1110374669","title":"Summit Therapeutics：将启动一系列新的III期Harmoni-Gi3临床试验，详细信息将于2026年第一季度发布","url":"https://stock-news.laohu8.com/highlight/detail?id=1110374669","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110374669?lang=zh_cn&edition=full","pubTime":"2025-10-20 18:49","pubTimestamp":1760957349,"startTime":"0","endTime":"0","summary":"Summit Therapeutics：将启动一系列新的III期Harmoni-Gi3临床试验，详细信息将于2026年第一季度发布","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","BK4139","LU2488822045.USD"],"gpt_icon":0},{"id":"1123453947","title":"Summit Therapeutics 发布2025年第三季度及截至9月30日的九个月财务结果和运营进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1123453947","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123453947?lang=zh_cn&edition=full","pubTime":"2025-10-20 18:46","pubTimestamp":1760957181,"startTime":"0","endTime":"0","summary":"Summit Therapeutics 发布2025年第三季度及截至9月30日的九个月财务结果和运营进展","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2488822045.USD","SMMT"],"gpt_icon":0},{"id":"1194256836","title":"伊沃赛单抗与化疗相较于替雷利珠单抗及化疗在中国Harmoni-6研究中降低鳞状非小细胞肺癌患者疾病进展或死亡风险40%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194256836","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194256836?lang=zh_cn&edition=full","pubTime":"2025-10-19 22:31","pubTimestamp":1760884305,"startTime":"0","endTime":"0","summary":"伊沃赛单抗与化疗相较于替雷利珠单抗（PD-1抑制剂）加化疗，在中国进行的Harmoni-6研究中，在一线治疗鳞状非小细胞肺癌患者时，降低了疾病进展或死亡的风险40%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","SMMT","BK4139"],"gpt_icon":0},{"id":"1124798722","title":"Summit Therapeutics扩展Ivonescimab全球III期开发计划，启动1L结直肠癌的Harmoni-Gi3研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1124798722","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124798722?lang=zh_cn&edition=full","pubTime":"2025-10-17 19:01","pubTimestamp":1760698900,"startTime":"0","endTime":"0","summary":"Summit Therapeutics扩展Ivonescimab全球III期开发计划，启动1L结直肠癌的Harmoni-Gi3研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2488822045.USD","SMMT"],"gpt_icon":0},{"id":"2564589614","title":"坐享康方生物(09926)创新药红利 合作伙伴Summit(SMMT.US)获H.C.Wainwright上调目标价至50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564589614","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564589614?lang=zh_cn&edition=full","pubTime":"2025-09-01 14:12","pubTimestamp":1756707123,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，H.C. Wainwright发 表研报，将Summit Therapeutics Inc.目标价从44美元上调至50美元，并维持“买入”评级。报告同时强调，当前正是布局Summit的良机，因其作为康方生物在美国市场的合作伙伴，具有独特优势。据了解，Summit是一家生物制药企业，致力于研发和商业化针对严重未满足医疗需求的创新疗法，其产品注重患者、家属、医生及社会效益，旨在延长寿命并提升生活质量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"c0b61b62afdaf0b7c4308a9678a42926","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1339833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","SMMT","09926","06978"],"gpt_icon":0},{"id":"2560594904","title":"美股前瞻 | 三大股指期货齐跌 美乌总统会谈在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2560594904","media":"智通财经","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560594904?lang=zh_cn&edition=full","pubTime":"2025-08-18 19:27","pubTimestamp":1755516457,"startTime":"0","endTime":"0","summary":"盘前市场动向1. 8月18日(周一)美股盘前，美股三大股指期货齐跌。美乌总统会谈在即，欧盟“组团”赴美。报道称，特朗普将于当地时间8月18日下午先与乌克兰总统泽连斯基会晤，随后再与到访的欧洲领导人举行更大范围会议，讨论乌克兰危机。美国总统特朗普多次批评美联储降息行动过于迟缓，引发了市场对美联储独立性的担忧。受此消息影响，截至发稿，Dayforce周一美股盘前大涨近27%。同期英国整体新车注册量同比下降约5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1331071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B19Z3B42.SGD","IE00BFXG1179.USD","SDS","SGXZ31699556.SGD","LU1791807156.HKD","SPY","LU0878866978.SGD","LU2213496289.HKD","LU1691799644.USD","IE00B1BXHZ80.USD","IE0005OL40V9.USD","BK4587","SG9999018865.SGD","UPRO","IE00BKDWB100.SGD","LU0061475181.USD","LU1571399168.USD","LU2764263203.CNY","LU0203201768.USD","LU0861579265.USD","LU0985489474.SGD","LU0345769128.USD","LU2237443622.USD","LU2361044949.HKD","SSO","LU1914381329.SGD","IE00BJJMRX11.SGD","TSYW.SI","LU0048573561.USD","IE00BWXC8680.SGD","LU0234570918.USD","IE00B3S45H60.SGD","ESmain","IVV","BK4516","LU1803068979.SGD","SH","OEF","IE00BZ199S13.USD",".SPX","LU1868836914.USD","LU1145028129.USD","OEX","MESmain","USJW.SI","SPXU","SMMT","LU0820561818.USD"],"gpt_icon":1},{"id":"2546777939","title":"暴跌超55%！关税，冲击显现！","url":"https://stock-news.laohu8.com/highlight/detail?id=2546777939","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546777939?lang=zh_cn&edition=full","pubTime":"2025-06-28 18:58","pubTimestamp":1751108280,"startTime":"0","endTime":"0","summary":"关税对全球汽车产业的冲击，正逐步显现！另外，数据显示，5月份，英国对美国市场的汽车出口量同比下跌55.4%，对欧盟市场的汽车出口量同比下跌22.5%。当地时间3月26日，美国总统特朗普在白宫签署行政令，宣布对所有进口汽车征收25%关税，相关措施于4月2日生效。根据协议，这些关税调整将于6月30日凌晨0时1分生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/zqgd/2025-06-28/doc-infcrsef1372858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2488822045.USD","BK4139","SMMT"],"gpt_icon":0},{"id":"2539220915","title":"Summit Therapeutics报告了 Ivonescimab在肺癌治疗中的混合试验结果Summit Therapeutics Reports Mixed Trial Results for Ivonescimab in Lung Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2539220915","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539220915?lang=zh_cn&edition=full","pubTime":"2025-05-30 21:10","pubTimestamp":1748610600,"startTime":"0","endTime":"0","summary":"by Mark Chiang马克·蒋Share To分享到Summit Therapeutics announced mixed results from a recent trial of its antibody treatment for lung cancer, Ivonescimab. The drug, which had previously outperformed Merck’s Keytruda in a direct comparison study, was closely monitored in this latest evaluation. The findings revealed both promising and less favorable outcomes, raising questions about its overall efficacy..Summit Therapeutics 近期对其用于治疗肺癌的抗体药物Ivonescimab进行的试验宣布了好坏参半的结果。The trial aimed to further assess Ivonescimab’s effectiveness as a treatment option for lung cancer patients. While the drug demonstrated certain advantages over existing therapies in specific areas, other aspects of the study showed less encouraging results. Summit Therapeutics has not yet disclosed detailed data from the trial but confirmed that the results were varied.该试验旨在进一步评估Ivonescimab作为肺癌患者治疗方案的有效性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530211531976b3081&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530211531976b3081&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","LU2488822045.USD","SMMT","BK4539","BK4007"],"gpt_icon":1},{"id":"2539222123","title":"Summit(SMMT.US)与康方生物合作药物3期试验获积极结果，有望冲刺FDA申报","url":"https://stock-news.laohu8.com/highlight/detail?id=2539222123","media":"智通财经","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539222123?lang=zh_cn&edition=full","pubTime":"2025-05-30 20:26","pubTimestamp":1748607982,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国生物技术公司Summit Therapeutics周五宣布，其与中国合作伙伴康方生物合作开发的主要资产ivonescimab在肺癌联合治疗方案的临床试验中达成了主要目标。关于耐受性，Summit表示，HARMONi试验未显示出新的安全性信号，在接受ivonescimab+化疗治疗的患者中约有57%出现了3级或以上的治疗相关不良事件，而对照组中该比例约为50%。该结果与康方生物在中国开展的HARMONi-A试验结果一致，该试验促成了中国监管机构去年批准ivonescimab联合化疗用于肺癌治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1299884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BPRC5H50.USD","09926","IE00B5MMRT66.SGD","LU0348783233.USD","LU1720050803.USD","LU1794554557.SGD","IE00B543WZ88.USD","LU0348784397.USD","SMMT","BK4139","LU0417516571.SGD","LU2488822045.USD","BK1574","BK1161"],"gpt_icon":1},{"id":"2518436278","title":"Summit Therapeutics Inc.盘中异动 股价大跌5.91%报16.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518436278","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518436278?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613469,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，Summit Therapeutics Inc.股票出现异动，股价急速跳水5.91%。截至发稿，该股报16.73美元/股，成交量9.1706万股，换手率0.01%，振幅0.81%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.59%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021310998a29c8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021310998a29c8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","LU2488822045.USD","SMMT","BK4139"],"gpt_icon":0},{"id":"2517516510","title":"Summit Therapeutics Inc.盘中异动 早盘股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517516510","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517516510?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:34","pubTimestamp":1741271643,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时34分，Summit Therapeutics Inc.股票出现波动，股价急速下跌5.06%。截至发稿，该股报18.56美元/股，成交量5.6688万股，换手率0.01%，振幅2.05%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.64%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223403abeb7870&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223403abeb7870&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","SMMT","BK4139","LENZ"],"gpt_icon":0},{"id":"2516650980","title":"Summit Therapeutics Inc.盘中异动 急速下跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516650980","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516650980?lang=zh_cn&edition=full","pubTime":"2025-03-04 03:36","pubTimestamp":1741030563,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日03时36分，Summit Therapeutics Inc.股票出现异动，股价快速下跌5.12%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.64%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Biocardia, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4550.84%、206.83%、181.58%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040336039637f047&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040336039637f047&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU2488822045.USD","SMMT","LENZ"],"gpt_icon":0},{"id":"2514376555","title":"Summit Therapeutics Inc.盘中异动 早盘大幅拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514376555","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514376555?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:26","pubTimestamp":1740756399,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日23时26分，Summit Therapeutics Inc.股票出现异动，股价急速拉升5.08%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Bioxcel Therapeutics, Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Puma Biotechnology Inc涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为1430.83%、405.61%、337.95%，振幅较大的相关个股有Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Bioxcel Therapeutics, Inc.，振幅分别为46.60%、43.37%、38.73%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228232639a2580f75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228232639a2580f75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU2488822045.USD","LENZ","SMMT"],"gpt_icon":0},{"id":"2514238400","title":"Summit Therapeutics Inc.2024财年实现净利润-2.21亿美元，同比增加64.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514238400","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514238400?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:01","pubTimestamp":1740672061,"startTime":"0","endTime":"0","summary":"2月28日，Summit Therapeutics Inc.公布财报，公告显示公司2024财年净利润为-2.21亿美元，同比增加64.07%；其中营业收入为0.00美元，每股基本收益为-0.31美元。机构评级：截至2025年2月28日，当前有6家机构对Summit Therapeutics Inc.目标价做出预测，其中目标均价为35.33美元，其中最低目标价为30.00美元，最高目标价为44.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228000106abdf84f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228000106abdf84f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SMMT"],"gpt_icon":0},{"id":"2514867183","title":"Summit Therapeutics Inc.盘中异动 大幅上涨5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514867183","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514867183?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:32","pubTimestamp":1740666751,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时32分，Summit Therapeutics Inc.股票出现异动，股价急速拉升5.22%。截至发稿，该股报19.26美元/股，成交量5.4943万股，换手率0.01%，振幅3.20%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.31%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223231a2567a36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223231a2567a36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SMMT","BK4139","LU2488822045.USD","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.smmttx.com","stockEarnings":[{"period":"1week","weight":0.0556},{"period":"1month","weight":0.0755},{"period":"3month","weight":-0.276},{"period":"6month","weight":-0.0864},{"period":"1year","weight":0.0687},{"period":"ytd","weight":0.0541}],"compareEarnings":[{"period":"1week","weight":0.0069},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0574},{"period":"6month","weight":0.1423},{"period":"1year","weight":0.1263},{"period":"ytd","weight":0.1677}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Summit Therapeutics Inc.于2013年11月22日在英格兰和威尔士注册成立，特拉华州的一家公司（“New Summit”）已成为该公司的后续发行方。该公司是一家生物制药公司，专注于发现、开发和商业化对患者、医生、护理人员和社会友好的药物疗法，旨在提高生活质量，延长潜在寿命，并解决严重的未满足的医疗需求。该公司的候选产品管线的设计目标是成为肿瘤治疗领域中对患者友好的、新时代的标准护理药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.119766},{"month":2,"riseRate":0.4,"avgChangeRate":0.024698},{"month":3,"riseRate":0.4,"avgChangeRate":0.028993},{"month":4,"riseRate":0.454545,"avgChangeRate":0.034483},{"month":5,"riseRate":0.545455,"avgChangeRate":0.099475},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.086722},{"month":7,"riseRate":0.636364,"avgChangeRate":0.088383},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.007003},{"month":9,"riseRate":0.363636,"avgChangeRate":0.075404},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.047867},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.015842},{"month":12,"riseRate":0.545455,"avgChangeRate":0.36349}],"exchange":"NASDAQ","name":"Summit Therapeutics PLC","nameEN":"Summit Therapeutics PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Summit Therapeutics PLC(SMMT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Summit Therapeutics PLC,SMMT,Summit Therapeutics PLC股票,Summit Therapeutics PLC股票老虎,Summit Therapeutics PLC股票老虎国际,Summit Therapeutics PLC行情,Summit Therapeutics PLC股票行情,Summit Therapeutics PLC股价,Summit Therapeutics PLC股市,Summit Therapeutics PLC股票价格,Summit Therapeutics PLC股票交易,Summit Therapeutics PLC股票购买,Summit Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Summit Therapeutics PLC(SMMT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}